The combination of CXCL12 and VEGF enhanced angiogenesis more than the monotherapies under conditions of hypercholesterolemia [51], in line with the enhanced effects of CXCL12-EPC cell therapy over LV-CXCL12 gene therapy and GFP-EPC cell therapy alone in protecting blood vessels, promoting the proliferation of NPCs in the SVZ, and the migration of OPCs in the perifocal area of the mouse brain in the weeks after ischemic brain injury. The gene discussed is VEGFA; the disease is Hypercholesterolemia.